ArticleFrontiers in endocrinology2011
Partitioning of bronchopulmonary carcinoids in two different prognostic categories by ki-67 score.
Article in Frontiers in endocrinology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The use of Ki-67 labeling index to grade pulmonary well-differentiated neuroendocrine neoplasms: current best evidence.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Pooled it
- Well-Differentiated Neuroendocrine Tumors of Lung: A Case Series Supporting the IARC/WHO Common Classification of Neuroendocrine Tumor Nomenclature and Grading.Endocrine pathology · 2026Article
- Diagnostic, Prognostic, and Predictive Role of Ki67 Proliferative Index in Neuroendocrine and Endocrine Neoplasms: Past, Present, and Future.Endocrine pathology · 2023Review
- Review
- Development and Validation of a DeepSurv Nomogram to Predict Survival Outcomes and Guide Personalized Adjuvant Chemotherapy in Non-Small Cell Lung Cancer.Frontiers in oncology · 2022Article
- The Ki-67 antigen in the new 2021 World Health Organization classification of lung neuroendocrine neoplasms.Pathologica · 2021Review
- KDM1A and KDM3A promote tumor growth by upregulating cell cycle-associated genes in pancreatic cancer.Experimental biology and medicine (Maywood, N.J.) · 2021Article
- Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature.Lung Cancer (Auckland, N.Z.) · 2020Review
- Spontaneous Partial Regression of a Carcinoid Tumor: Radiology May Not Capture the Real Picture.Turkish thoracic journal · 2019Article
- Long-term outcomes and prognostic factors of patients with surgically treated pulmonary atypical carcinoid tumors: our institutional experience with 68 patients.Journal of thoracic disease · 2018Article
- Classification of pulmonary neuroendocrine tumors: new insights.Translational lung cancer research · 2017Review
- Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017Article
- Tumor cell proliferation, proliferative index and mitotic count in lung cancer.Translational lung cancer research · 2016Article
- Ki-67 expression in pulmonary tumors.Translational lung cancer research · 2016Article
- Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life.Oncotarget · 2016Observational
- Review
- Interlaboratory variability of MIB1 staining in well-differentiated pancreatic neuroendocrine tumors.Virchows Archiv : an international journal of pathology · 2015Article
- Therapeutic biomarkers in lung neuroendocrine neoplasia.Endocrine pathology · 2014Review
- Automated quantification of Ki-67 proliferative index of excised neuroendocrine tumors of the lung.Diagnostic pathology · 2014Article
- Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors.Endocrine pathology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHistological distinction between typical and atypical bronchopulmonary carcinoids is based on mitotic activity and necrosis. Regardless of these two parameters, outcome after surgery is often unpredictable. In this study the prognostic value of different clinico-pathological factors was retrospectively analyzed in a large series of patients with bronchopulmonary carcinoid. MATERIALS AND
methodsThe long-term post-surgical outcome of 106 radically treated patients affected by bronchopulmonary carcinoid from two Italian centers was correlated with tumor characteristics assessed by combining conventional histology with a panel of immunohistochemical markers of neuroendocrine differentiation (chromogranin-A, NSE) and proliferation activity (Ki-67 score).
resultsCarcinoids were assessed as typical (TC = 75; 70.8%) and atypical (AC = 31; 29.2%). Mean follow-up was 8.3 years (range: 0-20; median: 8.0). All cases expressed neuroendocrine markers. At univariate analysis, tumor recurrence [14/75 TC (18.7%), 15/31 AC (48.4%)] correlated with carcinoid histotype (P = 0.003), tumor size (P = 0.012), mitotic index (P = 0.044), Ki-67 score (P < 0.0001), and synchronous node metastasis (P = 0.037). Of these, Cox multivariate analysis confirmed only Ki-67 score as independent predictor of disease recurrence (P = 0.009). The best cut-off for Ki-67 score (calculated by ROC curves) discriminating recurrent vs non-recurrent disease was 4% (sensitivity 79.3%; specificity 83.8%; area under the curve 0.85). By stratifying patients according to this cut-off, a significantly different disease-free survival was found (log-rank test P < 0.0001).
conclusionKi-67 score accurately separates bronchopulmonary carcinoids in two well-distinct histo-prognostic categories. Ki-67 score predicts the patients outcome better than mitotic count, histotype, and tumor stage and it is therefore helpful in establishing the appropriate follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.